Stryker stock: BTIG cuts target from USD 358.00 to USD 316.00

Published on 10/21/2026 at 17:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 6.59 billion, up 9.40 percent. Stryker stock costs EUR 262.10 on October 21, 2026, down 2.09 percent versus Xetra close.

Analyst target and reporting date

BTIG cut its Stryker target from USD 358.00 to USD 316.00 on October 12, 2026.
Second-quarter revenue reached USD 6.59 billion, up 9.40 percent year over year.
Stryker stock costs EUR 262.10 at Lang & Schwarz on October 21, 2026 at 5:03 p.m. CEST, down 2.09 percent versus the October 20 Xetra close and 33.23 percent below its 52-week high.
Stryker will discuss third-quarter results on October 29, 2026.

Stryker Corp., US8636671013, Illustration mit AI erstellt.

Stryker Corp. (ISIN US8636671013) faces a lower analyst valuation after BTIG cut its target from USD 358.00 to USD 316.00 on October 12, 2026, while the new target remains 7.48 percent above the NYSE price of USD 294.00. Markets Insider reported that BTIG maintained its Buy rating. Stryker stock was trading at EUR 262.10 at Lang & Schwarz on October 21, 2026 at 5:03 p.m. CEST, down 2.09 percent versus the Xetra close of October 20, 2026 (EUR 267.70).

BTIG target moves to USD 316.00

The BTIG revision gives investors a concrete measure of how the firm adjusted its view ahead of Stryker's third-quarter report. The USD 316.00 target is 11.73 percent below the former USD 358.00 target, while the rating remained Buy, according to the October 12 report.

Second-quarter revenue rose 9.40 percent

Stryker's operating picture still carries a strong comparison base. The Stock Observer reported second-quarter revenue of USD 6.59 billion, up 9.40 percent from the prior-year quarter. GAAP diluted earnings per share were USD 3.30, compared with USD 2.29 a year earlier, while net income reached USD 1.28 billion.

Stock trades 33.23 percent below high

On the NYSE, Stryker last traded at USD 294.00 on October 21, 2026 at 11:07 a.m. ET. Its same-session range was USD 293.69 to USD 303.66, and the 52-week range was USD 267.00 to USD 392.55. The current NYSE price is 25.08 percent above the 52-week low and 25.12 percent below the BTIG target.

Valuation and October 29 results

Stryker carried a price-to-earnings ratio of 30.48 and a market capitalization of USD 112.8 billion on October 21, 2026. Stryker scheduled its third-quarter financial results webcast for October 29, 2026 at 4:30 p.m. ET, with a release planned before the call. That date is the next defined test for revenue growth and earnings execution.

Comparison with peers

Stryker Corp. (NYSE, USD): down 2.09 percent, P/E 30.48, market capitalization USD 112.8 billion.

Zimmer Biomet (NYSE, USD): down 1.34 percent, P/E 23.07, market capitalization USD 18.1 billion.

Medtronic (NYSE, USD): down 1.38 percent, P/E 22.98, market capitalization USD 119.4 billion.

Target cut meets a scheduled test

BTIG's lower target and Stryker's October 29 reporting date create two separate reference points for investors. The target revision is measurable, while the upcoming results will provide the next reported comparison for revenue, earnings and management commentary.

The further course of trading is shown by the continuously updated real-time quote of Stryker stock.